Flinders University-ko ikertzaileekin lankidetzan egindako argitalpenak (44)

2024

  1. A genome-wide association analysis reveals new pathogenic pathways in gout*

    Nature Genetics

  2. Bacille Calmette-Guérin vaccination to prevent febrile and respiratory illness in adults (BRACE): secondary outcomes of a randomised controlled phase 3 trial

    eClinicalMedicine, Vol. 72

  3. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom

    Journal of medical economics, Vol. 27, Núm. 1, pp. 109-125

  4. Specific and off-target immune responses following COVID-19 vaccination with ChAdOx1-S and BNT162b2 vaccines—an exploratory sub-study of the BRACE trial

    eBioMedicine, Vol. 103

2023

  1. Bacillus Calmette-Guérin vaccination for protection against recurrent herpes labialis: a nested randomised controlled trial

    eClinicalMedicine, Vol. 64

  2. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

    JAMA Neurology, Vol. 80, Núm. 7, pp. 702-713

  3. Demystifying Ocular Syphilis–A Major Review

    Ocular Immunology and Inflammation, Vol. 31, Núm. 7, pp. 1425-1439

  4. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

    Journal of neurology, neurosurgery, and psychiatry, Vol. 94, Núm. 12, pp. 1004-1011

  5. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

    European Journal of Neurology, Vol. 30, Núm. 4, pp. 1014-1024

2022

  1. Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study

    Neurology, Vol. 98, Núm. 24, pp. E2401-E2412

  2. Confirmed disability progression as a marker of permanent disability in multiple sclerosis

    European Journal of Neurology, Vol. 29, Núm. 8, pp. 2321-2334

  3. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

    Neurology, Vol. 99, Núm. 17, pp. E1926-E1944

2021

  1. Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis—Report 1: Guidelines for Initiating Antitubercular Therapy in Tubercular Choroiditis

    Ophthalmology, Vol. 128, Núm. 2, pp. 266-276

  2. Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis—Report 2: Guidelines for Initiating Antitubercular Therapy in Anterior Uveitis, Intermediate Uveitis, Panuveitis, and Retinal Vasculitis

    Ophthalmology, Vol. 128, Núm. 2, pp. 277-287

  3. Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis

    Multiple Sclerosis Journal, Vol. 27, Núm. 5, pp. 755-766

  4. Factors associated with surgeon recommendation for additional cast immobilization of a CT-verified nondisplaced scaphoid waist fracture

    Archives of Orthopaedic and Trauma Surgery, Vol. 141, Núm. 11, pp. 2011-2018

2020

  1. Delay from treatment start to full effect of immunotherapies for multiple sclerosis

    Brain, Vol. 143, Núm. 9, pp. 2742-2756

  2. Risk of secondary progressive multiple sclerosis: A longitudinal study

    Multiple Sclerosis Journal, Vol. 26, Núm. 1, pp. 79-90

  3. Standardization of Nomenclature for Ocular Tuberculosis–Results of Collaborative Ocular Tuberculosis Study (COTS) Workshop

    Ocular Immunology and Inflammation, Vol. 28, Núm. sup1, pp. 74-84

  4. The Collaborative Ocular Tuberculosis Study (COTS) Consensus (CON) Group Meeting Proceedings

    Ocular Immunology and Inflammation, Vol. 28, Núm. sup1, pp. 85-95